{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T05:38:13Z","timestamp":1759815493468,"version":"3.41.2"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2021.627565","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T06:19:59Z","timestamp":1616653199000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Editorial: Skin Autoimmunity"],"prefix":"10.3389","volume":"12","author":[{"given":"Khalaf","family":"Kridin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian D.","family":"Sadik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Sch\u00f6n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Loser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(93)90244-F","article-title":"Defining criteria for autoimmune diseases (Witebsky\u2019s postulates revisited)","volume":"14","author":"Rose","year":"1993","journal-title":"Immunol Today"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.13964","article-title":"Dermatological complications of therapy with biologics in inflammatory autoimmune diseases","volume":"17","author":"Sondermann","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"B3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/ddg.14128","article-title":"Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update","volume":"18","author":"K\u00e4hler","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.13761","article-title":"Skin inflammation associated with arthritis, synovitis and enthesitis. Part 2: rheumatoid arthritis, reactive arthritis, Reiter\u2019s syndrome, Lyme borreliosis, dermatomyositis and lupus erythematosus","volume":"17","author":"Schempp","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151093","article-title":"Melanocyte antigen triggers autoimmunity in human psoriasis","volume":"212","author":"Arakawa","year":"2015","journal-title":"J Exp Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis","volume":"5","author":"Lande","year":"2014","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10090.x","article-title":"The role of T-cell reactivity towards the autoantigen \u03b1-NAC in atopic dermatitis","volume":"164","author":"Heratizadeh","year":"2011","journal-title":"Br J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13075-019-2052-2","article-title":"Proposition of a novel animal model of systemic sclerosis induced by type V collagen in C57BL\/6 mice that reproduces fibrosis, vasculopathy and autoimmunity","volume":"21","author":"Teodoro","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14124","article-title":"Cytokines of the IL-17 family in psoriasis","volume":"18","author":"Lauffer","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01323","article-title":"The Interleukin-23\/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis","volume":"9","author":"Sch\u00f6n","year":"2018","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13100","article-title":"HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment","volume":"42","author":"West","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31189-3","article-title":"Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial","volume":"390","author":"Papp","year":"2017","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1056\/NEJM197304262881715","article-title":"Occlusive vascular disease in psoriatic patients","volume":"288","author":"McDonald","year":"1973","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07562.x","article-title":"Psoriasis: a possible risk factor for development of coronary artery calcification","volume":"156","author":"Ludwig","year":"2007","journal-title":"Br J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15444","article-title":"Neurological Disorders are Associated with Bullous Pemphigoid","author":"Papakonstantinou","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2017.3066","article-title":"The association between bullous pemphigoid and neurological disorders: a systematic review","volume":"27","author":"Milani-Nejad","year":"2017","journal-title":"Eur J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.09.010","article-title":"BP180 Autoantibodies Target Different Epitopes in Multiple Sclerosis or Alzheimer\u2019s Disease than in Bullous Pemphigoid","volume":"139","author":"Tuusa","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00220","article-title":"The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15540","article-title":"Impact of diet and genes on murine autoimmune pancreatitis","volume":"24","author":"Jaster","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1038\/s41467-019-11952-w","article-title":"Gene-diet interactions associated with complex trait variation in an advanced intercross outbred mouse line","volume":"10","author":"Vorobyev","year":"2019","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"B28","article-title":"Cytokines in autoimmune bullous skin diseases. Epiphenomena or contribution to pathogenesis","volume":"144","author":"Ludwig","year":"2009","journal-title":"G Ital Dermatol Venereol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2015.00206","article-title":"Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment","volume":"22","author":"Hirose","year":"2017","journal-title":"Mol Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402688","article-title":"Caspase-1-Independent IL-1 Release Mediates Blister Formation in Autoantibody-Induced Tissue Injury through Modulation of Endothelial Adhesion Molecules","volume":"194","author":"Sadeghi","year":"2015","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.09.003","article-title":"IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid","author":"Chakievska","year":"2018","journal-title":"J Autoimmun"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1684\/ejd.2019.3497","article-title":"Possible involvement of IgE antibody in epidermolysis bullosa acquisita: detection and correlation","volume":"29","author":"Oya","year":"2019","journal-title":"Eur J Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02331","article-title":"The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid","volume":"10","author":"Messingham","year":"2019","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.11.031","article-title":"Eosinophils Mediate Tissue Injury in the Autoimmune Skin Disease Bullous Pemphigoid","volume":"138","author":"Lin","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01477","article-title":"Complement Activation in Autoimmune Bullous Dermatoses: A Comprehensive Review","volume":"10","author":"Edwards","year":"2019","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00306","article-title":"Perspective from the 5th International Pemphigus and Pemphigoid Foundation scientific conference","volume":"5","author":"Lee","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"adv00055","DOI":"10.2340\/00015555-3400","article-title":"Drug Development in Pemphigoid Diseases","volume":"100","author":"Bieber","year":"2020","journal-title":"Acta Derm Venereol"},{"volume-title":"Lichen Planus","year":"2020","author":"Arnold","key":"B38"},{"key":"B39","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jaci.2018.02.044","article-title":"TH1\/TH17\u00a0cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus.[letter]","volume":"142","author":"Schmidt","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddx328","article-title":"Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling","volume":"26","author":"Dand","year":"2017","journal-title":"Hum Mol Genet"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-011-2319-2","article-title":"[Chronic pruritus in autoimmune dermatoses : results of a comparative survey]","volume":"63","author":"Schr\u00f6der","year":"2012","journal-title":"Hautarzt"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14207","article-title":"The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study","volume":"174","author":"Nemoto","year":"2016","journal-title":"Br J Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00296","article-title":"Diagnosis of Autoimmune Blistering Diseases","volume":"5","author":"Witte","year":"2018","journal-title":"Front Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01974","article-title":"Serological Diagnosis of Autoimmune Bullous Skin Diseases","volume":"10","author":"Saschenbrecker","year":"2019","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00218","article-title":"The evolving story of autoantibodies in Pemphigus vulgaris: development of the \u201csuper compensation hypothesis\u201d","volume":"5","author":"Sinha","year":"2018","journal-title":"Front Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Primers"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.627565\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T23:03:05Z","timestamp":1698102185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.627565\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2021.627565"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.627565","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"article-number":"627565"}}